Boston Scientific Corp (BSX)vsNasdaq Inc (NDAQ)
BSX
Boston Scientific Corp
$53.93
-4.67%
HEALTHCARE · Cap: $84.08B
NDAQ
Nasdaq Inc
$88.91
-0.10%
FINANCIAL SERVICES · Cap: $50.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 280% more annual revenue ($20.61B vs $5.42B). NDAQ leads profitability with a 35.3% profit margin vs 17.3%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).
BSX
Strong Buy71
out of 100
Grade: B
NDAQ
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.7%
Fair Value
$46.22
Current Price
$53.93
$7.71 premium
Intrinsic value data unavailable for NDAQ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Strong operational efficiency at 20.6%
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 48.4%
Large-cap with strong market position
Earnings expanding 33.8% YoY
Areas to Watch
No major concerns identified
Expensive relative to growth rate
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : NDAQ
The strongest argument for NDAQ centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 35.3% and operating margin at 48.4%. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : NDAQ
The primary concerns for NDAQ are PEG Ratio, P/E Ratio.
Key Dynamics to Monitor
NDAQ carries more volatility with a beta of 0.99 — expect wider price swings.
NDAQ is growing revenue faster at 13.7% — sustainability is the question.
NDAQ generates stronger free cash flow (629M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (71/100 vs 69/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Nasdaq Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?